Cue Biopharma is trading 5.65% up now at $29.75 after a sharp multi-session advance, with no clear catalyst identified.
- Shares gained 15.44% on August 25 and 7.81% on August 26.
- No new company-specific announcement dated August 28, 2026 was identified.
- The latest highlighted investor-relations release is the August 3 CFO appointment and CUE-221 investigational-new-drug submission; the broader market is only modestly higher.